The remaining two trials, a trial with tirzepatide in people with obesity and type 2 diabetes (SURMOUNT-2) [50] and a cardiovascular outcomes trial with semaglutide (SUSTAIN 6) [31], had a duration of 72 and 104 weeks, respectively
Unlike the kinases for which multiple inhibitors have been developed and tested in clinical trials, the most common palmitoylation inhibitor, 2-BP, cannot be used clinically because of its significant off-target activity and toxicity, including inhibition of mitochondrial fatty acid oxidation (247, 248)
These predispositions may help provide context for how your body might respond to different semaglutide doses, supporting more informed conversations with your provider about dosing strategy
Alternatively, the 14-item Hospital Anxiety and Depression Scale (HADS) may be used [128]
We pay special attention to any history of medical conditions, such as medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, to ensure patient safety